IL1B and autoimmune thrombocytopenic purpura: EJSW may treat ITP by inhibiting the expression of TNF-α, IL-1β, and other inflammatory factors, and by protecting vascular integrity through AGE-RAGE signalling, VEGF signalling, and complement and coagulation cascade signalling pathways.